EBOS Group Management

Management criteria checks 2/4

EBOS Group's CEO is John Cullity, appointed in Apr 2018, has a tenure of 6.08 years. total yearly compensation is A$7.76M, comprised of 20.6% salary and 79.4% bonuses, including company stock and options. directly owns 0.013% of the company’s shares, worth A$783.72K. The average tenure of the management team and the board of directors is 4.5 years and 3.8 years respectively.

Key information

John Cullity

Chief executive officer

AU$7.8m

Total compensation

CEO salary percentage	20.6%
CEO tenure	6.1yrs
CEO ownership	0.01%
Management average tenure	4.5yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Cullity's remuneration changed compared to EBOS Group's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	AU$257m
Sep 30 2023	n/a	n/a	AU$255m
Jun 30 2023	AU$8m	AU$2m	AU$253m
Mar 31 2023	n/a	n/a	AU$243m
Dec 31 2022	n/a	n/a	AU$233m
Sep 30 2022	n/a	n/a	AU$218m
Jun 30 2022	AU$6m	AU$1m	AU$203m
Mar 31 2022	n/a	n/a	AU$198m
Dec 31 2021	n/a	n/a	AU$194m
Sep 30 2021	n/a	n/a	AU$190m
Jun 30 2021	AU$4m	AU$1m	AU$185m
Mar 31 2021	n/a	n/a	AU$180m
Dec 31 2020	n/a	n/a	AU$174m
Sep 30 2020	n/a	n/a	AU$168m
Jun 30 2020	AU$4m	AU$1m	AU$163m
Mar 31 2020	n/a	n/a	AU$157m
Dec 31 2019	n/a	n/a	AU$152m
Sep 30 2019	n/a	n/a	AU$145m
Jun 30 2019	AU$2m	AU$1m	AU$138m
Mar 31 2019	n/a	n/a	AU$136m
Dec 31 2018	n/a	n/a	AU$134m
Sep 30 2018	n/a	n/a	AU$136m
Jun 30 2018	AU$1m	AU$287k	AU$137m

Compensation vs Market: John's total compensation ($USD5.10M) is above average for companies of similar size in the Australian market ($USD2.15M).

Compensation vs Earnings: John's compensation has increased by more than 20% in the past year.

CEO

John Cullity

6.1yrs

Tenure

AU$7,756,764

Compensation

Mr. John Cullity has been Non-Executive Director of Terry White Group Limited since March 29, 2018. Mr. Cullity has been Chief Executive Officer of EBOS Group Limited since April 1, 2018. Mr. Cullity serve...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Cullity	Chief Executive Officer	6.1yrs	AU$7.76m	0.013% A$ 783.7k
Leonard Hansen	CFO & Chief Accountant	4.2yrs	no data	0.0076% A$ 473.9k
Mithran Naiker	Chief Information Officer	no data	no data	no data
Janelle Cain	General Counsel	9.3yrs	no data	no data
Jacinta McCarthy	Group General Manager of Human Resources	4.5yrs	no data	no data
Simon Bunde	Executive General Manager of Strategic Operations	no data	no data	no data
Julie Dillon	Chief Executive Officer of Animal Care	2.5yrs	no data	no data
Matthew Muscio	Chief Executive Officer of Medical Technology	1.9yrs	no data	no data
Brett Barons	Chief Executive Officer of Symbion	6.3yrs	no data	0.024% A$ 1.5m

4.5yrs

Average Tenure

Experienced Management: EBO's management team is considered experienced (4.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mark Bloom	Independent Director	1.7yrs	AU$122.43k	no data
Elizabeth Coutts	Independent Chairman	20.8yrs	AU$376.92k	0.056% A$ 3.5m
Stuart McLauchlan	Independent Director	4.8yrs	AU$220.71k	0.0013% A$ 79.5k
Tracey Batten	Independent Director	2.8yrs	AU$179.24k	0.00078% A$ 48.8k
Julie Tay	Independent Director	less than a year	AU$19.99k	no data
Peter Williams	Independent Director	10.8yrs	AU$164.04k	no data

3.8yrs

Average Tenure

60.5yo

Average Age

Experienced Board: EBO's board of directors are considered experienced (3.8 years average tenure).

EBOS Group Management

Management criteria checks 2/4

Key information

Recent management updates

EBOS Group Limited Announces Chief Financial Officer Changes

Insider recently sold AU$4.9m worth of stock

EBOS Group Limited Announces the Appointment of Mark Bloom as an Independent Director, Effective 16 September 2022

Ebos Group Limited Announces Resignation of Nick Dowling as Director

Independent Director recently bought AU$55k worth of stock

EBOS Group Limited, Annual General Meeting, Oct 19, 2021

Recent updates

EBOS Group Limited Announces Chief Financial Officer Changes

Insider recently sold AU$4.9m worth of stock

First half dividend of NZ$0.60 announced

First half 2024 earnings released: EPS: AU$0.71 (vs AU$0.70 in 1H 2023)

EBOS Group Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Now 20% undervalued

EBOS Group Limited to Report First Half, 2024 Results on Feb 21, 2024

EBOS Group Limited (NZSE:EBO) acquired additional 39% stake in Transmedic Pte Ltd. from TS Lee for approximately SGD 120 million.

Paragon Care Reportedly Taps Rothschild for Defence Amid Buyout Talk

EBOS Reportedly Runs Eye over Paragon Care after Abandoning Greencross Pursuit

EBOS Not to Proceed with Acquisition in Animal Care Segment

EBOS Not to Proceed with Acquisition in Animal Care Segment

Now 21% undervalued

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended June 30, 2023, Payable on 29 September, 2023

Now 21% undervalued

Upcoming dividend of NZ$0.60 per share at 3.0% yield

Ebos Group Limited Announces Dividend, Payable on 29 September 2023

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorates as stock falls 17%

Now 26% undervalued after recent price drop

First half 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited to Report Q2, 2023 Results on Feb 22, 2023

EBOS Group Limited Announces the Appointment of Mark Bloom as an Independent Director, Effective 16 September 2022

Upcoming dividend of NZ$0.51 per share

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Dividend for the Six Months Ended June 30, 2022, Payable on 30 September, 2022

Upcoming dividend of NZ$0.49 per share

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

EBOS Group Limited Announces Fully Franked Ordinary Dividend for the Six Months Ended December 31, 2021, Payable on March 18, 2022

Ebos Group Limited Announces Resignation of Nick Dowling as Director

Independent Director recently bought AU$55k worth of stock

Price target increased to AU$31.66

EBOS Group Limited Announces Supplementary Dividend for the Six Months Ended June 30, 2021, Payable on Sept. 24, 2021

Upcoming dividend of NZ$0.48 per share

EBOS Group Limited (EBOS) acquired Sentry Medical.

Full year 2021 earnings released: EPS AU$1.13 (vs AU$1.01 in FY 2020)

EBOS Group Limited (NZSE:EBO) acquired Pioneer Medical Limited for AUD 40 million.

Price target raised to AU$25.70

First half 2021 earnings released: EPS AU$0.57 (vs AU$0.51 in 1H 2020)

Revenue beats expectations

EBOS Group Limited (NZSE:EBO) acquired Vet Distribution Business of Clifford Hallam Healthcare Pty Ltd for AUD 9.2 million.

EBOS Group Limited (NZSE:EBO) acquired CH2 Vet for AUD 9.2 million.

EBOS Group Limited, Annual General Meeting, Oct 19, 2021

New 90-day high: AU$27.92

New 90-day high: AU$25.25

EBOS Group Limited (NZSE:EBO) entered into an agreement to acquire Cryomed Aesthetics Pty Limited for AUD 14.1 million.

New 90-day high: AU$23.26

New 90-day high - AU$21.38

Full year earnings released - EPS AU$1.01

New 90-day low - AU$20.00

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age